Dr. Wyatt receives a CIHR Early Career Investigator Award

Date Posted: 
2017-12-07

Dr. Alex Wyatt has been awarded a 2017 CIHR Early Career Investigator Award.  His project aims to develop a procedure that will enable the identification of metastatic bladder cancer patients most likely to respond to specific therapies. The funding partners are the Institute of Cancer Research and AstraZeneca Canada Inc., and the award is for $345,000 over 3 years.

Chemotherapy has historically been the most effective treatment for metastatic disease, but long-term survival has been a rarity. Recently, new drugs including immunotherapies are showing significant promise, but only a small proportion of patients respond to these treatments and there currently is no reliable way of predicting who the responders will be.

Dr. Wyatt established the groundwork for this project during the first three years of his faculty appointment, during which time he worked closely with clinical collaborators to develop a blood test that can identify tumor DNA present in a small blood sample. Preliminary work with this circulating tumor DNA (ctDNA) suggests that mutations detected in ctDNA accurately reflect cancer itself, meaning that a patient’s metastatic bladder cancer can be profiled without the need for a tissue biopsy (see Vandekerkhove et. al., Clin Cancer Res. 2017 Nov 1;23(21):6487-6497 PMID: 28760909).

His awarded project,"Circulating tumour DNA as a precision oncology tool for metastatic bladder cancer," will identify mutations in the ctDNA of hundreds of Canadians with metastatic bladder cancer that are being treated with chemotherapy or immunotherapy. His research team will determine which mutations can predict a patient’s subsequent response to treatment using our rare combination of cancer bioinformatics and clinical oncology. Success with this project will help explain why some metastatic bladder cancers are intrinsically responsive or resistant to the most commonly used therapies. Furthermore, Dr. Wyatt and his team will have developed a clinically-practical framework (requiring only a blood sample) that may ultimately help align patients with therapies which would provide the best chance of success.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

VPC Terry Fox team 2016

Terry Fox Run: Sunday September 16, 2018

On Sunday September 16, the fundraising Terry Fox walk/run/ride is taking place across Canada.  We are grateful for our  grant support provided by The Terry Fox Foundation and Terry Fox Research Institute continously since 1998 - click here to donate to our team (opens in new window)

 

Vancouver

18th Annual Pacific Northwest Prostate Cancer Conference: Sat Sept 22, 2018

The 18th Annual Pacific Northwest Prostate Cancer Conference for patients, their families and health care professionals will be held in Vancouver on Saturday September 22, from 8 AM to 4 PM.  Click here for further details and to purchase tickets ($30, includes lunch). (Opens in new window)

 

Employment

Work at the Vancouver Prostate Centre

Thursday, July 26, 2018

Dr. Gleave awarded the 2018 Dr. Chew Wei Memorial Prize in Cancer Research

Dr. Gleave
Tuesday, May 29, 2018

Three VPC trainees receive 2018 VCHRI Rising Star Awards

2018 Rising Star Awardees
DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.